Merus N.V. (MRUS) to Post Q2 2017 Earnings of ($0.72) Per Share, Wedbush Forecasts
Merus N.V. (NASDAQ:MRUS) – Stock analysts at Wedbush lifted their Q2 2017 EPS estimates for shares of Merus N.V. in a research note issued to investors on Wednesday. Wedbush analyst D. Nierengarten now forecasts that the biotechnology company will post earnings of ($0.72) per share for the quarter, up from their previous forecast of ($0.78). Wedbush has a “Outperform” rating and a $32.00 price objective on the stock. Wedbush also issued estimates for Merus N.V.’s Q3 2017 earnings at ($0.78) EPS, Q4 2017 earnings at ($0.93) EPS, FY2018 earnings at ($4.74) EPS, FY2019 earnings at ($5.29) EPS, FY2020 earnings at ($5.23) EPS and FY2021 earnings at ($3.23) EPS.
Other research analysts also recently issued reports about the stock. ValuEngine raised shares of Merus N.V. from a “sell” rating to a “hold” rating in a research report on Saturday, May 20th. Zacks Investment Research downgraded shares of Merus N.V. from a “hold” rating to a “sell” rating in a research report on Friday, May 5th. Citigroup Inc. cut shares of Merus N.V. from a “buy” rating to a “neutral” rating and set a $31.00 price target on the stock. in a research note on Tuesday, March 21st. Finally, Jefferies Group LLC restated a “buy” rating and set a $33.00 price target on shares of Merus N.V. in a research note on Wednesday, April 26th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. Merus N.V. currently has an average rating of “Hold” and a consensus price target of $26.00.
Shares of Merus N.V. (MRUS) opened at 16.85 on Friday. Merus N.V. has a 12 month low of $8.00 and a 12 month high of $33.63. The firm’s market capitalization is $312.40 million. The firm’s 50-day moving average is $17.76 and its 200 day moving average is $21.82.
Hedge funds have recently bought and sold shares of the company. Spark Investment Management LLC purchased a new stake in Merus N.V. during the first quarter valued at about $458,000. Renaissance Technologies LLC bought a new stake in Merus N.V. during the first quarter valued at $549,000. Norges Bank bought a new stake in Merus N.V. during the fourth quarter valued at $790,000. Victory Capital Management Inc. bought a new stake in Merus N.V. during the first quarter valued at $976,000. Finally, Iguana Healthcare Management LLC boosted its stake in Merus N.V. by 16.7% in the first quarter. Iguana Healthcare Management LLC now owns 175,000 shares of the biotechnology company’s stock valued at $4,268,000 after buying an additional 25,000 shares during the period. Institutional investors and hedge funds own 32.59% of the company’s stock.
Merus N.V. Company Profile
Receive News & Stock Ratings for Merus N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus N.V. and related stocks with our FREE daily email newsletter.